Ibex Investors’s Scinai Immunotherapeutics SCNI Stock Holding History

Ibex Investors’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-322	Closed	-$12.6M	–	54
2020 Q3	$12.6M	Sell	322 -6	-2%	-$230K	6.64%	9
2020 Q2	$7.47M	Sell	328 -29	-8%	-$467K	3.55%	11
2020 Q1	$2.75M	Sell	357 -2	-0.6%	-$17.7K	2.77%	9
2019 Q4	$3.33M	Hold	359	–	–	0.06%	11
2019 Q3	$2.14M	Hold	359	–	–	0.13%	20
2019 Q2	$2.07M	Hold	359	–	–	0.17%	25
2019 Q1	$1.95M	Hold	359	–	–	0.17%	27
2018 Q4	$1.71M	Hold	359	–	–	0.28%	22
2018 Q3	$2.01M	Hold	359	–	–	1.12%	19
2018 Q2	$2.4M	Hold	359	–	–	1.36%	17
2018 Q1	$1.95M	Hold	359	–	–	1.61%	15
2017 Q4	$1.92M	Buy	+359	New	+$2.26M	1.12%	13

Other funds holding SCNI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $6.54B AUM

Ibex Investors's SCNI Position: Q4 2020 in Review

Ibex Investors sold out of Scinai Immunotherapeutics (SCNI) in Q4 2020, closing a stake of 322 shares — an estimated $12.6M sold.

Ibex Investors first reported a position in SCNI in Q4 2017 and held it in 12 quarters. The position peaked at $12.6M in Q3 2020. 10 funds tracked by Wall St. Rank hold SCNI as of Q4 2020.

Ibex Investors reported no remaining Scinai Immunotherapeutics position as of Q4 2020 after selling out during the quarter.
Ibex Investors sold 322 Scinai Immunotherapeutics shares in Q4 2020, an estimated $12.6M.
Ibex Investors first reported a position in Scinai Immunotherapeutics in Q4 2017 and held it in 12 quarters.
Ibex Investors's Scinai Immunotherapeutics position peaked at $12.6M in Q3 2020.
10 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2020.

Based on Ibex Investors's 13F filing for Q4 2020, filed 3 Feb 2021.